Y0000522
炔诺酮
European Pharmacopoeia (EP) Reference Standard
别名:
17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H26O2
化学文摘社编号:
分子量:
298.42
Beilstein:
1915671
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
norethisterone
制造商/商品名称
EDQM
mp
205-206 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
−20°C
SMILES字符串
[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C
InChI
1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1
InChI key
VIKNJXKGJWUCNN-XGXHKTLJSA-N
基因信息
human ... PGR(5241)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Norethisterone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险分类
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
法规信息
涉药品监管产品
此项目有
Derin J Cobia et al.
Schizophrenia research, 139(1-3), 1-6 (2012-06-01)
Cortical abnormalities are considered a neurobiological characteristic of schizophrenia. However, the pattern of such deficits as they progress over the illness remains poorly understood. The goal of this project was to assess the progression of cortical thinning in frontal and
Patricia M LoRusso et al.
Cancer chemotherapy and pharmacology, 71(1), 193-202 (2012-10-16)
Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma. Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI
H F Taitel et al.
International journal of fertility and menopausal studies, 40(4), 207-223 (1995-07-01)
Norethindrone is utilized for numerous noncontraceptive therapies, especially during the menopause. Through an analysis of the literature we have described the pharmacological profile of norethindrone and the potential therapeutic implications of low-dose therapies, with an emphasis on endometrial pathology, climacteric
P Vercellini et al.
Human reproduction (Oxford, England), 27(12), 3450-3459 (2012-08-29)
Does surgical or medical treatment for endometriosis-associated severe deep dyspareunia achieve better results in terms of patients' satisfaction (main study outcome), variation of coital pain and frequency of intercourse? Surgery and progestin therapy were equally effective in the treatment of
Kelli Stidham Hall et al.
Contraception, 86(6), 653-658 (2012-06-12)
Progestin-only contraceptive pills (POPs) offer a safe and effective contraceptive option, particularly for women at increased risk of venous thromboembolism. However, the prevalence of POP use among women in the United States is unknown. We analyzed population-based data from 12,279
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持